Xencor and MorphoSys Initiate Phase 1 Study of Anti-CD19 Antibody in Chronic Lymphocytic Leukemia Monrovia, Calif. December 2, 2010 Xencor, Inc. and MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) announced today that they have initiated Phase 1 testing for XmAb®5574 (MOR208),
Xencor Receives Milestone Payment from Boehringer Ingelheim Under Antibody Technology License Agreement Monrovia, CAOctober 12, 2010 Xencor, Inc. announced today that the Company received a milestone payment from Boehringer Ingelheim. The payment was triggered by the regulatory
MorphoSys and Xencor Sign License and Collaboration Agreement for Clinical Antibody Program Martinsried/Munich, Germany, and Monrovia, Calif. June 28, 2010 MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) and US-based biopharmaceutical company Xencor, Inc., announced today the
Xencor Appoints Edgardo Baracchini, Ph.D., to Chief Business Officer Monrovia, Calif. February 9, 2010 Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, announced today the appointment of Edgardo Baracchini, Ph.D., to chief
Data Published in Nature Biotechnology Shows Fc Engineering Improves Antibody Efficacy and Convenience Monrovia, Calif. January 19, 2010 A Nature Biotechnology article published online January 17 reveals that Xencor Inc.'s proprietary Fc engineering extends the half-life of antibodies
Xencor Receives Milestone Payment from Pfizer Under Antibody Technology License Agreement Monrovia, CADecember 16, 2009 Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, announced today that the Company received a milestone
Xencor Appoints Former ZymoGenetics CEO, Bruce Carter, to Chairman of the Board Monrovia, CADecember 7, 2009 Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, announced today the appointment of Bruce Carter, Ph.D.
Xencor Licenses Antibody Optimization Technology Monrovia, Calif. November 30, 2009 Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation and biosuperior antibodies, announced today that it has licensed its XmAb® and Xtend™ technology
Xencor Appoints Jeffrey V. Ravetch of The Rockefeller University to its Scientific Advisory Board Monrovia, CAJune 29, 2009 Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation antibodies, today announced the addition of Jeffrey Ravetch,